Table 1. Blood Biochemistry Data for F344 Rats Fed a Diet Containing 0.2% bLF for 40 weeks

	Control	0.2% bLF
GOT (IU/L)	135.1 ± 30.1	100.0 ± 24.0[c]
GPT (IU/L)	85.3 ± 11.7	68.3 ± 19.0[b]
γ-GTP (IU/L)	N.D.	N.D.
ALP (IU/L)	714.6 ± 108.5	585.3 ± 93.7[c]
Creatinine (mg/dL)	0.3 ± 0.028	0.28 ± 0.025
BUN (mg/dL)	18.5 ± 2.00	16.0 ± 1.33[c]
Total Protein (g/dL)	6.7 ± 0.38	6.6 ± 0.22
Albumin (g/dL)	4.3 ± 0.26	4.4 ± 0.13
Cholesterol (mg/dL)	77.1 ± 10.9	78.3 ± 8.26
Triglyceride (mg/dL)	117.3 ± 44.9	83.9 ± 21.8[a]
Blood Glucose (g/dL)	174.4 ± 24.1	168.5 ± 21.3
Serum Iron (μg/dL)	152.7 ± 19.5	155.9 ± 25.6

Values are means±S.D. [a,b,c] $P<0.05$, $P<0.01$, $P<0.005$ compared to the control group. N.D., Not detected

Discussion

The present 40 week-chronic oral administration of dietary 0.2% bLF (Experiment I) demonstrated no cause of any toxicological lesions in male F344 rats. Decrease in serum GOT, GPT and ALT may be related to improvement of the impaired liver function possibly due to aging. Similarly, the lower level of BUN may be at least partly associated with protection of kidney function.

The findings, however, could not be confirmed in Experiment II in which animals were fed longer duration because serum was not taken. However, the serum triglyceride level was clearly decreased to 72 % of the control level. Although serum glucose level did not decrease, the result may be beneficial for protecting against the metabolic syndrome associated with hyperlipidemi. Administration of bLF has been reported to induce the production of cytokine IL-18 in the mouse small intestine (Kuhara et al., 2000). Recently, Netea et al. reported that deficiency of interleukin-18 leads to hyperphagia, obesity and hyperglycemia resulting from insulin resistance in Il-18 knockout mice (Netea et al., 2006). Furthermore, the molecular mechanisms responsible for the hepatic insulin resistance in Il-18 knockout mice involve an enhanced expression of genes associated with gluconeogenesis in the liver, resulting from defective phosphorylation of STAT3 (Netea et al., 2006). Decreased triglyceride level might therefore imply induction of cytokine IL-18 by lactoferrin in experiment I. Practically, serum IL-18 levels are significantly increased in patients with HVC associated chronic hepatitis C (Ishii, 2004). In this context it should be noted that blood biochemistry revealed significant lowering of AST and ALT in the 0.2% bLF treatment group, which might be related to gluconeogenesis in the liver.

In experiment II, there was no evidence of long term toxicity or carcinogenicity in either sex of rat fed 5.0% bLF for 60 or 65 weeks. Total and daily intake in the 5.0% bLF group were 46,201 g or 54,175 g, and 109 g or 119 g, when extrapolated to male or female human beings, respectively. Thus, we conclude that these ranges of dosage levels can be administered to humans safely in clinical trials. Our results are in line with the lack of any adverse effects reported in lactoferrin-treated patients with chronic hepatitis C, healthy subjects positive for helicobacter pylori infection and high risk subjects of colon and lung cancers (Tanaka et al., 1999; Iwasa et al., 2002; Okuda et al., 2005).

Accordingly, the results indicated that the NOAEL for bLF with 60 or 65 weeks dietary treatment is at least 5.0% for both sexes. Therefore, the results of the current study provide strong support for safety in accepted dose ranges of lactoferrin and related compounds for further clinical and intervention studies.

Acknowledgements

This work was supported in part by a Grant-in-Aid for the Second Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare, by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare in Japan, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

References

Arnold RR, Brewer M, Gauthier JJ (1980). Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. *Infect Immun*, **28**, 893-8.

Bartlett MS (1937). Properties of sufficiency and statistical tests. *Proc Royal Soc*, **A160**, 268-82.

Bellamy W, Takase M, Yamauchi K, et al (1992). Identification of the bactericidal domain of lactoferrin. *Biochem Biophys Acta*, **1121**, 130-6.

Brock J (1995). Lactoferrin: a multifunctional immunoregulatory protein? *Immunol Today*, **16**, 417-9.

Bullen JJ (1975). Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. *Postgrad Med J*, **51**, 67-70.

Dunnett CW (1955). A multiple procedure for comparing several treatments with a control. *J Amer Stat Assoc*, **50**, 1096-121.

Fisher RA (1955). Statistical methods and scientific induction. *J Royal Stat Soc, Series "B"*, **17**, 69-78.

Gad SC, Weil CS (1989. Statistics for toxicologists, in: Hayes AW (Ed). Principles and methods of toxicology. Raven Press, Ltd. 435-83.

Goodman DG, Ward JM, Squire RA, Chu KC, Linhart MS (1979). Neoplastic and nonneoplastic lesions in aging F344 rats. *Toxicol Applied Pharmacol*, **48**, 237-48.

Haseman JK, Arnold J, Eustis SL (1990). Tumor incidences in Fischer 344 rat: NTP historical data. In: Boorman GA, Eustis SL, Elwell MR, Montogomery CA Jr, Mackenzie WF (Eds), Pathology of the Fischer Rat. Academic Press Inc., San Diego, CA, pp.555-64.

Iigo M, Kuhara T, Ushida Y, et al (1999). Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. *Clin Exp Metastasis*, **17**, 35-40.

Ishii K, Matsumaru K, Takamura N, et al (2004). Bovine lactoferrin induces serum IL-18 in patients with chronic hepatitis C. *J Med Soc Toho Univ*, **51**, 214-21.

Iwasa M, Kaito M, Ikoma J, et al (2002). Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. *Am J Gastroenterol*, **97**, 766-7.

Kuhara T, Iigo M, Ito T, et al (2000). Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestine epithelium. *Nutr Cancer*, **38**, 192-9.

Lash JA, Coates TD, Lafuze J, Baehner RL, Boxer LA (1983). Plasma lactoferrin reflects granulocyte activation *in vivo*. *Blood*, **61**, 885-8.

Lönnerdal B, Iyer S (1995). Lactoferrin: molecular structure and biological function. *Annu Rev Nutr*, **15**, 93-110.

Masson PL, Heremans JF, Schonne E (1969). Lactoferrin, an iron-binding protein in neutrophilic leukocytes. *J Exp Med*, **130**, 643-58.

Netea MG, Joosten LAB, Lewis E, et al (2006). Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. *Nature Med*, **12**, 650-6.

Okuda M, Nakazawa T, Yamauchi K, et al (2005). Bovine lactoferrin is effective to suppress helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study. *J Infect Chemother*, **11**, 265-9.

Sekine K, Watanabe E, Nakamura J, et al (1997). Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. *Jpn J Cancer Res*, **88**, 523-6.

Steel RGD (1959). A multiple comparison rank sum test: Treatments versus control. *Biometrics*, 15, 560-72.

Tanaka K, Ikeda M, Nozaki A, et al (1999). Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. *Jpn J Cancer Res*, **90**, 367-71.

Tomita M, Bellamy W, Takase M, et al (1991). Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. *J Dairy Sci*, **74**, 4137-42.

Tsuda H, Sekine K, Takasuka N, Toriyama-Baba H, Iigo M (2000a). Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. *Biofactors*, **12**, 83-8.

Tsuda H, Sekine K, Ushida Y, et al (2000b). Milk and dairy products in cancer prevention: focus on bovine lactoferrin. *Mutat Res*, **462**, 227-33.

Tsuda H, Ohshima Y, Nomoto H, et al (2004). Cancer prevention by natural compounds. *Drug Metab Pharmacokinet*, **19**, 245-63.

Wakabayashi H, Takase M, Tomita M (2003). Lactoferricin derived from milk protein lactoferrin. *Curr Pharm Res*, **9**, 1277-87.

Yamauchi K, Toida TS, Nagano E, et al (2000a). 13-week oral repeated administration toxicity study of bovine lactoferrin in rats. *Food Chem Toxicol*, **38**, 503-12.

Yamauchi K, Toida T, Kawai A, et al (2000b). Mutagenicity of bovine lactoferrin in reverse mutation test. *J Toxicol Sci*, **25**, 63-6.

ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

Biochimie 91 (2009) 86–101

BIOCHIMIE

www.elsevier.com/locate/biochi

Research paper

Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine

Masaaki Iigo [a,b], David B. Alexander [b], Ne Long [b], Jiegou Xu [b], Katsumi Fukamachi [b], Mitsuru Futakuchi [b], Mitsunori Takase [c], Hiroyuki Tsuda [b,*]

[a] *Cancer Prevention Basic Research Project, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Tokyo*
[b] *Department of Molecular Toxicology, Nagoya City University, Graduate School of Medical Sciences, Nagoya-shi, Aichi-ken, Japan*
[c] *Food Science & Technology and Nutritional Science Institutes, Morinaga Milk Industry Co., Ltd, Zama, Japan*

Received 30 January 2008; accepted 20 June 2008
Available online 27 June 2008

Abstract

Oral administration of bovine lactoferrin (bLF) inhibits carcinogenesis in the colon and other organs in rats, and lung metastasis in mice. A likely mechanism by which bLF mediates its anticarcinogenesis effects is by enhanced expression of cytokines and subsequent activation of immune cells. Oral administration of bLF enhances expression of interleukin-18 (IL-18) mRNA in the mucosa of the small intestine of mice. Importantly, the pepsin hydrolysate of bLF (bLFH) also induced expression of IL-18 mRNA in the mouse small intestine and a peptide produced by pepsin digestion of bLF, bovine lactoferricin (bLFcin), induced expression of mature IL-18 in organ culture. In addition to IL-18, bLF and bLFcin both induced significant increases in caspase-1 activity in peritoneal macrophages and in organ cultures. The increase of mature IL-18 by macrophages was inhibited by caspase-1 inhibitor: caspase-1 is known to cleave the proform of IL-18 to produce active mature IL-18. Finally, bLF also induced expression of IFNγ by peritoneal macrophages. Importantly, in IFNγ knockout (GKO) mice, bLF administration resulted in increased expression of caspase-1 protein, but induction of IL-18 mRNA, caspase-1 activity, and mature IL-18 was not observed. These results indicate that orally administered bLF can induce expression of IFNγ and caspase-1 in the small intestine. IFNγ in turn increases expression of target genes, including IL-18. Active caspase-1 then cleaves pro-IL-18 to generate mature IL-18. Thus, bLF activates an effector pathway mediated by IFNγ, caspase-1, and IL-18. We also show that ingested bLF is able to activate more than a single effector pathway. For example, in GKO mice while bLF administration could not activate the IFNγ/caspase-1/IL-18 effector pathway, it was able to inhibit tumor growth and metastasis by activation of an IFNα/IL-7 effector pathway.
© 2008 Elsevier Masson SAS. All rights reserved.

Keywords: Lactoferrin; Innate immune system; Cytokine; Chemoprevention; Carcinogenesis

1. Introduction

Lactoferrin (LF), an approximately 80 kDa iron binding glycoprotein initially purified from milk, is an important component of the innate immune system. A potent antimicrobial and antiviral agent [1–5], LF is a major component of antimicrobial host defense and is found in a variety of exocrine secretions, e.g., tears, nasal exudate, saliva, bronchial mucus, gastrointestinal fluids, cervicovaginal mucus, and seminal fluid. In addition to its presence in mucosal secretions, LF is released by activated neutrophils at septic sites.

The concentration of LF in human colostrum is particularly high (7–10 mg/ml) [6] resulting in ingestion of 1–2 g/day for several months by a suckling infant [7]. It is thought that orally ingested LF may be able to interact with epithelial cells and immune cells in the mucosa of the intestine: ingested LF is reported to stimulate cytokine

* Corresponding author at: Department of Molecular Toxicology, Nagoya City University, Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-ch-, Mizuho-ku, Nagoya-shi, Aichi-ken 467-8601, Japan. Tel.: +81 52 853 8991; fax: +81 52 853 8996.

E-mail address: htsuda@med.nagoya-cu.ac.jp (H. Tsuda).

0300-9084/$ - see front matter © 2008 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.biochi.2008.06.012

production [8] and enhance mucosal immunity [9], NK cell activity [10,11], LAK activity [11], neutrophil activity [12,13], and macrophage cytotoxicity [14,15]. Previously we found that the pro-inflammatory cytokine interleukin-18 (IL-18) was produced by epithelial cells of the small intestine following administration of bLF [9,16]. IL-18 enhances Th1 type T and NK cell responses and generates $CD8^+$T cells [17].

Bezault et al. [18] report a protective effect of human-LF against the growth of solid tumors and the development of metastases in mice. bLF also inhibits lung metastasis of B16 melanoma and colon 26 tumor cells in mice [19,20] and is protective against tongue, esophagus, intestinal, lung, and bladder carcinogenesis in rats [21–24]. bLF administration results in a significant increase of $CD4^+$ and $CD8^+$T cells and asialo GM_1^+ (NK) cells in the blood [16] and in the lymphoid tissues and lamina propria of the small intestine [9]: $CD8^+$T and asialo $GM1^+$ cells exhibit marked cytotoxicity against Co26Lu cells *in vitro* [16]. The observed increase in T and NK cells may be due to the increased levels of mature IL-18 produced by epithelial cells of the small intestine after treatment with bLF [16].

In Co26Lu bearing-SCID mice, which are deficient in T and B cells, bLF also showed significant inhibition of tumor growth (Fig. 1) and lung metastatic colony formation [7]. However, the number of lung metastatic colonies was markedly increased when these mice were treated with anti-asialo GM_1 antibodies to weaken their NK cell activity. Bezault et al. [18] also report that LF-mediated antitumor effects were lost upon elimination of NK cell activity by pretreatment of mice with anti-asialo GM_1 antibodies. These results demonstrate the importance of activated NK cells for LF-mediated inhibition of tumor growth and metastasis.

The immunomodulatory and antitumor activities of bLF suggest that it may be a promising chemopreventer of carcinogenesis [25,26]. In this study we investigated pathways by which ingested bLF can exert its effects.

2. Materials and methods

2.1. bLF, bLFH, bLFcin and bTF

Bovine lactoferrin (bLF) (purity: greater than 96% of total protein by HPLC; endotoxin: less than 5.0 pg/mg of bLF; iron content: 143 ± 19 ng/mg of bLF, $n = 3$), a pepsin-generated hydrolysate of bLF (bLFH: endotoxin, 101.3 ± 25.7 pg/mg of bLFH; iron content, 100 ± 0 ng/mg of bLFH, $n = 3$), and lactoferricin (bLFcin: endotoxin, 101.3 ± 25.7 pg/mg of bLFcin, $n = 3$) were obtained from Morinaga Milk Industry Co., Ltd. (Zama, Japan). Bovine transferrin (bTF) (purity: greater than 98% of total protein by agarose electrophoresis; endotoxin, 16.4 ± 2.8 pg/mg of bTF; iron content, 13 ± 3 ng/mg of bTF, $n = 3$) was purchased from Sigma Co. Ltd. (St. Louis, MO). Endotoxin (by the modified limulus test) and iron (by the 2-nitroso-5-[*N*-*n*-propyl-*N*-(3-sulfopropyl)amino]phenol test) content were determined by SRL Inc., Hachioji, Japan.

2.2. Cytokines and antibodies

Anti-asialo GM_1 Ab was purchased from Wako Pure Chemical Industries (Osaka, Japan; caspase-1/ICE inhibitor (Acyl-Tyr-Val-Ala-Asp-chloromethylketone) was purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya, Japan); recombinant murine IFNγ was purchased from Intergen Company (Purchase, NY); recombinant murine IL-7 was purchased from PeproTech House (London, England); recombinant murine IL-18 was purchased from Medical & Biological Laboratories Co., Ltd.; recombinant IFNαA/D (2.04×10^7 IU/ml) was obtained from Nippon Roche Research Center, (Kamakura, Japan); anti-mouse IFNα antibody (clone F18, rat IgG_1) was purchased from HyCult Biotechnology b.v.; goat anti-murine IL-1β (M-20, goat IgG) was purchased from Santa Cruz Biotechnology, Inc.; anti-murine IL-7 polyclonal antibody was purchased from Pepro Tech EC Ltd.; anti-mouse IL-12 antibody (p40/p70) was purchased from PharMingen, BD Biosciences; rabbit anti-mouse IL-15 antibody was purchased from Torrey Pines Biolabs, Inc.



Fig. 1. Importance of activated NK cells for bLF-mediated inhibition of tumor growth (Co26Lu tumor-bearing SCID mice). 1×10^5 cells/mouse were subcutaneously implanted into the right thigh of SCID mice (Charles River Japan, female). bLF was administered at 30 or 300 mg/kg per day on days 5–9 and 12–16. Anti-asialo GM_1 Ab was injected (dilute 1/40, 0.2 ml/mouse i.v.) on days 5, 7, 12, and 14. The longest (a) and shortest (b) diameters of tumors at the Co26Lu cell injection site were measured twice a week using calipers, and the volume was calculated using the formula: $ab^2/2$ (mm^3). The experiment was terminated 22 days after implantation. The symbols represent the mean and standard error of tumor sizes ($n = 5–7$). *$p < 0.05$, Dunnett's multiple comparison *t*-test.

(Houston, TX); anti-rat IFNγ antibody (clone DB-1, mouse IgG_1) was purchased from BioLegend (San Diego, CA); and anti-TNFα (L-19) polyclonal antibody was purchased from Santa Cruz Biotechnology, Inc. Rabbit anti-human lactoferrin, specific for human lactoferrin, and rabbit anti-bovine lactoferrin antibodies, specific for bovine lactoferrin, were obtained from Morinaga Milk Industry Co. Ltd. (Zama, Japan). Anti-human IL-12/IL-23 p40 (clone: C8.3, mouse IgG_1) was purchased from BioLegend; anti-human IL-18 antibody (clone: 159-12B, rat IgG_{2a}:detects both pro-IL-18 and mature IL-18) and anti-human IFNα antibody (clone: #14, mouse IgG_1) were purchased from Medical & Biological Laboratories Co., Ltd.; anti-human IFNγ antibody (clone: MD-1, mouse IgG_1) was purchased from BioLegend (San Diego, CA).

2.3. Mice

BALB/c mice (wild type mice), 5-week-old male and female, were obtained from Charles River Japan (Atsugi, Japan). IFNγ knockout mice (mice with a targeted disruption of the IFNγ gene, BALB/c-$Ifng^{tm1Ts}$, 4 ~ 5-weeks-old female, GKO mice) [27] were purchased from the Jackson Laboratory, Bar Harbor, ME. The animals were allowed free access to CE-2 pellet diet (CLEA Japan, Tokyo, Japan) and water, and were maintained in plastic cages on woodchip bedding under specific pathogen-free conditions in our animal facility with a controlled temperature of 24 ± 2 °C, humidity 60 ± 10%, and a 12 h light–dark cycle. All experiments were initiated when the mice became 6 weeks-old, and performed according to "Guide for the Care and Use of Laboratory Animals" of the Animal Study Committee of National Cancer Center Research Institute, Tokyo, Japan.

2.4. Organ culture of the small intestine

BALB/c mice were anesthetized with diethyl ether and then killed. The jejunum was excised (2 cm) and then washed with physiological saline. The jejunum was turned inside out and cultured in RPMI-1640 culture medium at 37 °C for 30 min with bLF, bTF, or bLFcin as shown in Fig. 2. After the 30 min culture period, the tissue specimens were cut perpendicularly with scissors and opened onto glass plates. The entire surface (epithelium, lamina propria, submucosa) of the jejunum was harvested by scraping with a slide glass. The sample was then placed on an aluminum plate cooled by acetone-dry ice and pressed flat using another plate. These samples were stored at −80 °C until use.

2.5. Peritoneal macrophage culture

Mice were injected intraperitoneally with 4 ml of thioglycollate broth (3 g/100 ml, Eiken Chemical Co. Ltd., Tokyo). Four days after injection, peritoneal exudate macrophages were obtained: using a plastic 10 ml syringe with a 22-gauge needle, mice were injected intraperitoneally with saline and massaged and the saline solution containing peritoneal exudate macrophages was recovered. Macrophages were washed once with Hanks' balanced salt solution. The harvested cells were centrifuged at $200 \times g$ for 10 min, resuspended in culture medium (RPMI-1640, 10% FBS), and plated into a 24-well tissue culture plate (2×10^6 cells/2 ml/well). After incubation for 2 h, non-adherent cells were removed by vigorous washing, and fresh culture medium (RPMI-1640, 5% FBS) was added to the monolayer.

2.6. Spleen cell culture

Mice were anaesthetized and killed and the spleen harvested. Spleens were minced in petri dishes containing 5 ml media and pressed through a 120-stainless-steel mesh. Cells obtained were washed with Hanks' balanced salt solution, centrifuged at $200 \times g$ for 10 min, resuspended in culture medium (RPMI-1640, 10% FBS), and plated into a 24-well tissue culture plate (2×10^6 cells/2 ml/well).

2.7. Enzyme-linked immunosorbent assay (ELISA) – frozen organ culture samples

ELISA was used to determine the levels of various cytokines. Frozen tissues were homogenized with a Sonifier 450 (Branson Ultrasonics Corp., Daburg, CT) in lysis buffer (0.067 M phosphate buffer, pH 7.2, 1% Nonidet P-40, 0.5% sodium deoxycholic acid, 0.1% sodium dodecyl sulfate, and 10 μg/ml phenylmethylsulfonyl fluoride, 2.5 μg/ml leupeptin and 20 U/ml aprotinin), homogenates were clarified by centrifugation at 15,000 rpm for 10 min at 4 °C, and the supernatants were collected and stored at −80 °C until testing. ELISA kits for murine IL-1β were purchased from Genzyme Techne (Minneapolis, MN). Mature IL-18 levels were determined using a mouse IL-18 ELISA kit (minimum detection limit: 25.0 pg/ml) purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya, Japan).

2.8. Enzyme-linked immunosorbent assay (ELISA) – peritoneal macrophage, RAW 264.7 cells, and spleen cell cultures

Peritoneal macrophages and spleen cells were harvested as described above. RAW 264.7 mouse macrophages were obtained from Riken (Tsukuba, Japan). Cells were plated into 24-well tissue culture plates (2×10^6 cells/2 ml/well). After incubation for 24 h in 300 μg/ml bLF, cells were harvested and lysed in 100 μl of chilled lysis buffer (0.067 M phosphate buffer, pH 7.2, 1% Nonidet P-40, 0.5% sodium deoxycholic acid, 0.1% sodium dodecyl sulfate, and 10 μg/ml phenylmethylsulfonyl fluoride, 2.5 μg/ml leupeptin and 20 U/ml aprotinin), and then clarified by centrifugation at 15,000 rpm for 10 min. The supernatants were collected and stored at −80 °C until testing. An ELISA kit for mature mIL-18 (minimum detection limit: 25.0 pg/ml) (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) was used to measure IL-18 levels.

2.9. Enzyme-linked immunosorbent assay (ELISA) – peritoneal macrophage cultures

Peritoneal macrophages were harvested as described above. Cells were plated into 24-well tissue culture plates



Fig. 2. Effects of bLF and bLFcin on caspase-1 activity and the level of mature IL-18 in the mucosa of organ cultured small intestine. Mouse jejunum in organ culture was incubated with lactoferrin (A) ($n = 7$) or lactoferricin (B) ($n = 3$) for 30 min, and caspase-1 activity and mature IL-18 or IL-1β levels were measured by ELISA. Error bars represent the standard error. $*p < 0.05$, Dunnett's multiple comparison t-test.

(2×10^6 cells/2 ml/well). After incubation for 24 h in bLF, rmIFNγ, anti-mIFNγ antibody, or caspase-1 inhibitor, cells were harvested and lysed in 100 μl of chilled lysis buffer (0.067 M phosphate buffer, pH 7.2, 1% Nonidet P-40, 0.5% sodium deoxycholic acid, 0.1% sodium dodecyl sulfate, and 10 μg/ml phenylmethylsulfonyl fluoride, 2.5 μg/ml leupeptin and 20 U/ml aprotinin), and then clarified by centrifugation at 15,000 rpm for 10 min. The supernatants were collected and stored at −80 °C until testing. An ELISA kit for mature mIL-18 (minimum detection limit: 25.0 pg/ml) (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) was used to measure IL-18 levels.

2.10. Caspase-1 activity

For assaying the activity of caspase-1, colorimetric protease assay kits were used (BioVision Research Products, Mountain View, CA). The samples were diluted to 200 μg protein in 50 μl Cell Lysis buffer and then 50 μl of Reaction buffer containing 10 mM DTT and 5 μl of 4 mM Tyr-Val-Ala-Asp-pNA

(chromophore *p*-nitroanilide) was added. The samples were incubated at 37 °C for 2 h. Caspase-1 activity levels were determined at 405 nm in a microtiter plate reader. In some experiments, Acyl-Tyr-Val-Ala-Asp-chloromethylketone (Bachem Biochemica GmbH, Heidelberg, Germany) at a concentration of 50 μM was added to inhibit caspase-1 activity; the inhibitor was applied 30 min before bLF addition.

2.11. Western blot analysis of cell cultures

Peritoneal macrophages were harvested as described above; Lewis Lung carcinoma cells and MCF7 human breast cancer epithelial cells were obtained from the National Cancer Center Research Institute (Tokyo, Japan); SW620 colon carcinoma cells were obtained from the American Type Culture Center (Rockville, MD); and SK-MEL 19 melanoma cells [28] were obtained from the Medical Research and Development Center, the Tokyo Metropolitan Institute of Medical Science (Tokyo, Japan). Cells were seeded in 24 well plates in RPMI-1640 medium with 10% FBS at a density of 1×10^6 cells/well and incubated for 24 h. The medium was then changed to serum-free medium containing various concentration of bLF. After a 24 h incubation, cells were washed twice with serum-free medium and lysed in 75 μl chilled lysis buffer containing 125 mM Tris–HCl (pH 6.8), 4.3% SDS, 30% glycerol, 10% 2-mercaptoethanol, 0.01% BPB, and protease inhibitor cocktail "Complete Mini" (Roche, Mannheim, Germany). Lysates were sonicated and clarified by centrifugation at 15,000 rpm for 45 min at 4 °C. Ten μg of each sample was separated by SDS-PAGE on 15/25% polyacrylamide gradient gels (Multigel II Mini, Daiichi Pure Chemicals Co. Ltd., Tokyo). Proteins were transferred to PVDF membrane (Immobilon-P, Millipore Corp., Bedford, MA) and detected by Western blot with appropriate antibodies. Immunoreactive bands were visualized with Amersham ECL Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK). Densitometric analysis of digitized blot images was carried out using NIH Image software.

2.12. Protein assay

Total protein content of the samples was assayed using Coomassie Dry Protein Assay Plates (Pierce, Rockford, IL) with bovine serum albumin as the protein standard (Fraction V, Sigma Chemical Co. St. Louis, MO).

2.13. Lung metastasis assay

Colon carcinoma 26 (obtained from the Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan), are of BALB/c origin and have low metastatic potential. Metastatic tumor cells (Co26Lu) were obtained by sequential selection of tumor colonies in the lung: colon carcinoma 26 cells were subcutaneously implanted into the back of synergistic BALB/c mice and after tumor formation, colonies in the lung were recovered and cells from these lung metastases were subcutaneously implanted into the back of another mouse. After several rounds of sequential selection, highly metastatic Co26Lu cells were obtained.

Freshly excised Co26Lu cells from tumor-bearing mice were minced in Hanks' balanced salt solution (Life Technologies, Grand Island, NY) and strained through a 120-stainless-steel mesh. Viability was determined by trypan blue dye exclusion. Cells were diluted to the desired concentration and 1×10^5 cells/mouse were subcutaneously implanted into the right thigh of GKO and BALB/c mice ($n = 15$). bLF was administered at 30 or 300 mg/kg per day on days 3–7, 10–14, and 17–21 and the mice were killed on day 22. The lungs were excised and fixed in acetone and lung metastases were counted.

2.14. Treatment with bLF, bLFcin, and bTF and preparation of tissues

Normal BALB/c (WT) and GKO mice were used (five mice/group). bLF, bLFH, and bTF were dissolved in physiological saline (3 or 30 mg/ml) and administered at 30 mg/kg per day in consecutive treatments for 7 days or a single administration at 300 mg/kg. Three hours after the last oral administration of bLF, bLFH or bTF the mice were anesthetized with diethyl ether and killed. The small intestine, jejunum and ileum, was excised and washed with physiological saline. It was then cut perpendicularly with scissors and opened onto a glass plate. The entire surface (epithelium, lamina propria, submucosa) of the ileum was harvested by scraping with a slide glass. A portion of the harvested mucosa was used for RNA extraction; the remaining mucosa was placed on an aluminum plate cooled by acetone-dry ice and pressed flat using another plate. These samples were stored at −80 °C until use. The jejunum was fixed in acetone and used for immunohisochemistry.

2.15. Enzyme-linked immunosorbent assay (ELISA) – frozen tissue samples

ELISA was used to determine the levels of various cytokines. Frozen tissues were homogenized with a Sonifier 450 (Branson Ultrasonics Corp., Daburg, CT) in lysis buffer (0.067 M phosphate buffer, pH 7.2, 1% Nonidet P-40, 0.5% sodium deoxycholic acid, 0.1% sodium dodecyl sulfate, and 10 μg/ml phenylmethylsulfonyl fluoride, 2.5 μg/ml leupeptin and 20 U/ml aprotinin), homogenates were clarified by centrifugation at 15,000 rpm for 10 min at 4 °C, and the supernatants were collected and stored at −80 °C until testing. ELISA kits for murine IL-1β, IL-4, IL-6, IL-12, GM-CSF, and TNFα were purchased from Genzyme Techne (Minneapolis, MN). Mature IL-18 levels were determined using a mouse IL-18 ELISA kit (minimum detection limit: 25.0 pg/ml) purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya, Japan).

2.16. PCR detection of IL-7, IL-15, IL-18, and caspase-1 mRNA expression

For investigation of IL-7, IL-15 IL-18, and caspase-1 mRNA levels, in the intestinal epithelium, bLF was administered orally to tumor-bearing mice on day 7 or days 1–7,

and the mice were killed under deep anesthesia with diethyl ether 3 h after the last oral administration and the small intestine was immediately removed. Total RNAs from mucosal tissues were isolated using ISOGEN (Nippon Gene, Toyama, Japan), followed by ethanol precipitation. Aliquots (5 μg) of total RNA were subjected to a DNase I digestion before reverse transcription (RT) to eliminate any remaining genomic DNA. The RT reaction was carried out for 1 h at 42 °C in a reaction mixture (20 μl) containing 50 ng of oligo(dT)12–18 primer, dNTP (0.5 mM each of dATP, dGTP, dCTP and dTTP), 200 units of Superscript™II (Life Technologies Inc., Gaithersburg, MD) and the first strand buffer, and terminated by incubation at 95 °C for 5 min.

PCR was performed in a reaction mixture (30 μl) containing cDNA, primers (10 pmol each), 0.2 mM dNTP and 1.5 units of Takara Ex Taq™ DNA polymerase (Takara Shuzo, Kyoto, Japan) in Ex Taq buffer. Primers (5′–3′) specific for murine IL-7, IL-15, IL-18, caspase-1 and β-actin sequences [29–32] were as follows:

IL-7, GCGGATCCATGTTCCATGTTTCTTTTAG and GCAAGCTTGTTTATATACTGCCCTTC, 483 bp;
IL-15, GCGGATCCAATGAAAATTTTGAAACC and GCGAATTCAGTCAGGACGTGTTGATG, 508 bp;
IL-18, GCGAATTCCAATGGCTGCCATGTCAG and GCAAGCTTACCTAACTTTGATGTAAG, 599 bp;
Caspase-1, GCCTGCAGATGGCTGACAAGATCCTGAGG and
GCCTCGAGTTAATGTCCCGGGAAGAGGTAG, 1225 bp
β-actin, GCGGATCCATGGATGATGATATCGCCGC and GCAAGCTTCCTAGAAGCATTTGCGGTGG, 1144 bp.

Before the first cycle, a denaturation step was performed at 95 °C for 7 min, PCR was carried out using a PCR thermal cycler sp (Takara Shuzo, Kyoto, Japan) with a regimen of 95 °C for 1 min, 58 °C for 1 min, and 72 °C for 1 min (30 cycles), and a final extension period of 7 min at 72 °C. The products were analyzed by electrophoresis through 1.5% agarose gels and stained with ethidium bromide, and densitometric analysis of digitized gel images was carried out using NIH Image software.

2.17. Immunohistochemical studies

For investigation of the effect of bLF on immune cells, 3 h after the final oral administration of bLF (30 mg/kg per day for 7 days; four mice/group) mice were anesthetized and killed, and the jejunum was removed. Jejuna obtained from mice were fixed in acetone at 4 °C and embedded in paraffin. After cutting and deparaffination, sections were incubated in 1% skim milk (Yukijirushi, Sapporo, Japan) – PBS at room temperature for 1 h to block non-specific antigens.

$CD4^+$ and $CD8a^+$ cells were detected with rat-anti-mouse CD4 mAb and CD8a mAb (Japan BD Biosciences Pharmingen, Tokyo, Japan). After washing blocked sections three times, sections were incubated in PBS containing 10% hydrogen peroxide at room temperature for 30 min to remove endogenous peroxidase activity before antibody was added. Sections were then incubated with antibody in a humidified chamber at room temperature for 2 h. After washing, the sections were incubated with biotin-conjugated anti-rat IgG antibody (Vectastain Elite ABC kit, Vector Laboratories, Burlingme, CA) for 3 h. Labeled cells were visualized with 0.03% 3,3-diaminobezidine tetrahydrochroride solution containing 0.1% hydrogen peroxide for 5 min.

IgM^+ and IgA^+ cells were detected with goat anti-mouse IgM Ab-FITC and goat anti-mouse IgA Ab-FITC (Sigma). After washing blocked sections three times, sections were incubated with antibody in a humidified chamber at 4 °C for 2 h. Labeled cells were visualized by fluorescent microscopy.

IL-7, IFNα, and caspase-1 (p-20) expressing cells were detected with rat anti-mouse IL-7 Ab (PeproTech EC. Ltd. London, UK), rat anti-mouse IFNα mAb (HyCult Biotechnology b.v., Uden, The Netherlands), and rabbit anti-mouse caspase-1 (p-20) antibody (Santa Cruz Biotechnology), respectively. After washing blocked sections three times, sections were incubated in PBS containing 10% hydrogen peroxide at room temperature for 30 min to remove endogenous peroxidase activity before antibody was added. Sections were then incubated with antibody in a humidified chamber at room temperature for 2 h. After washing, the sections were incubated with biotin-conjugated anti-rat IgG antibody or biotin-conjugated anti-rabbit IgG antibody (Vectastain Elite ABC kit, Vector Laboratories, Burlingme, CA) for 3 h. Labeled cells were visualized with 0.03% 3,3-diaminobezidine tetrahydrochroride solution containing 0.1% hydrogen peroxide for 5 min.

Results were expressed as the mean of the number of positive cells in the lamina propria per 10 light microscope fields (×200).

2.18. Western blot analysis of frozen tissue samples

Frozen tissue samples (100 mg) were homogenized in 1 ml chilled lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail "Complete Mini™" (Roche, Mannheim, Germany). Lysates were centrifuged at 600 rpm for 20 min at 4 °C to remove nuclei and cell debris, and then clarified by centrifuged at 15,000 rpm for 45 min at 4 °C. Twenty μg of protein from each sample were separated by SDS-PAGE on 10% acrylamide, 0.2% bis gels. Proteins were transferred to Immobilon™ transfer membranes (Millipore Corp., Bedford, MA) and detected by Western blot with appropriate antibodies. Immunoreactive bands were visualized with ECL Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK). Densitometric analysis of digitized blot images was carried out using NIH Image software.

2.19. Treatment of GKO mice with rmIL-7, rmIL-18 or rIFNαA/D and metastasis assay

Co26Lu cells (1×10^5 cells/mouse) were subcutaneously implanted into the right thigh of GKO mice. Recombinant

murine IL-7 (*Escherichia coli*, PeproTech House, London, England), recombinant murine IL-18 (Medical & Biological Laboratories Co., Ltd.), and recombinant IFNαA/D (2.04×10^7 IU/ml, Nippon Roche Research Center, Kamakura, Japan) were administered intraperitoneally (i.p.) to GKO mice at 1 and 0.1 μg/mouse, 0.02 μg/mouse and 1×10^5 IU/mouse, respectively, on days 10, 13, 17, and 20. Endotoxin levels of rmIL-7 and IL-18 were less than 0.1 ng/μg protein by the LAL method. The longest (a) and shortest (b) diameters of tumors at the Co26Lu cell injection site were measured twice a week using calipers, and the volume was calculated using the formula: $ab^2/2$ (mm^3). The experiment was terminated 22 days after implantation, and the mice were killed. The lungs were removed, rinsed with saline, and fixed in acetone, and the lung metastatic colonies counted.

3. Results

3.1. Caspase-1 activity and generation of mature interleukin-18 levels in the mucosa of the small intestine in organ culture by bLF

In C57BL/6 or BALB/c mice, oral treatment with bLF or bLFcin increases mature IL-18 levels in the mucosa of the small and large intestines [7]. However, bLF is digested into numerous peptides by pepsin in the stomach [33]. We employed an organ culture system using mouse small intestine to investigate the ability of intact bLF and an N-terminal peptide fragment of bLF (bLFcin) to affect the activity of caspase-1 and the generation of mature IL-18: caspase-1 cleaves the proform of IL-18 to generate the 18 kDa bioactive molecule [34–36].

In organ culture experiments, caspase-1 activity and mature IL-18 levels in the mucosa of the small intestine were significantly increased following addition of bLF (Fig. 2A). Exposure to bLFcin also resulted in increases in caspase-1 activity and mature IL-18 levels (Fig. 2B). These results were specific since exposure to bTF did not result in elevated levels of mature IL-18, and exposure to bLF did not affect IL-1β levels. These results are similar to those obtained from previous *in vivo* experiments in which treatment with bLF or bLFcin caused an increase in IL-18 levels and caspase-1 activity in the mucosa of the small intestine [9]. Therefore, both intact bLF and an N-terminal peptide fragment of bLF, bLFcin, stimulate caspase-1 activity and the generation of mature IL-18.

3.2. bLF or bLFcin induction of cytokine production by peritoneal macrophages

Next, we investigated caspase-1 and cytokine production by peritoneal macrophages treated with bLF or bLFcin *in vitro*. Peritoneal macrophages, the macrophage cell line RAW264.7, and spleen cells were treated with bLF, and caspase-1 activity and mature IL-18 levels were measured. Treatment with 300 μg/ml bLF enhanced caspase-1 activity in peritoneal macrophages and possibly to some extent in spleen cells, but not in RAW264.7 cells (Fig. 3 left panel). bLF markedly enhanced production of mature IL-18 in peritoneal macrophages but not in Raw264.7 or spleen cells (Fig. 3 right panel). bLF-mediated induction of mature IL-18 by peritoneal macrophages was dose dependent and bovine transferrin (bTF) had no effect (Fig. 4). Recombinant murine interferon-gamma (rmIFNγ) also induced mature IL-18 production by peritoneal macrophages (Fig. 4). Importantly, bLF-mediated induction of mature IL-18 was abrogated by co-incubation of the cells with caspase-1 inhibitor (Acyl-Tyr-Val-Ala-Asp-chloromethylketone, Ac-YVAD-CMK) (Fig. 5). bLF-mediated induction of mature IL-18 was also inhibited by co-incubation with anti-mIFNγ antibody (Fig. 5). Finally, IFNγ induced production of mature IL-18 (Fig. 5), and this induction was inhibited by co-incubation of the cells with anti-mIFNγ antibody (data not shown), confirming the validity of this assay.

In Western blot analysis of macrophage lysates after addition of bLF or bLFcin at 1000 or 30 μg/ml, respectively, bLF induced expression of IFNγ and IL-15, and bLFcin induced expression of IL-15 (Fig. 6). Treatment with bLF decreased expression of IFNα while treatment with bLFcin decreased expression of TNFα (Fig. 6).



Fig. 3. Effects of bLF on caspase-1 activity and mature IL-18 production in peritoneal macrophages, RAW264.7 cells, and spleen (BALB/c mouse) cells. Cells were incubated for 24 h in bLF (300 μg/ml). Caspase-1 activity and mature IL-18 levels were determined by ELISA. Data are representative of two independent experiments.



Fig. 4. Effect of bLF, bTF, and rmIFNγ on the production of mature IL-18 by macrophages. Macrophages were incubated for 24 h in bLF, bTF or rmIFNγ and mature IL-18 levels were measured by ELISA. Error bars represent the standard error ($n = 3$). *$p < 0.05$, Dunnett's multiple comparison t-test.

3.3. Cytokine induction in various tumor cell lines by bLF or bLFcin

bLF can induce caspase-1 activity and the generation of mature IL-18 in mouse intestinal tissue and macrophages and IFNγ and IL-15 expression in macrophages; bLFcin can induce caspase-1 activity and the generation of mature IL-18 in mouse intestinal tissue and IL-15 expression in macrophages. We next investigated the effect bLF or bLFcin had on cytokine expression in mouse and human tumor cell lines: Lewis lung carcinoma was the mouse tumor cell line used, and SW620 (colon), MCF-7 (breast), and SK-MEL-19 (melanoma) were the human cell lines used.



Fig. 5. Caspase-1 inhibitor (YVAD) and IFNγ antibodies block mature IL-18 production by macrophages treated with bLF. Peritoneal macrophages were treated with bLF, bLF + the caspase-1 inhibitor YVAD or bLF + IFNγ antibodies, and mature IL-18 levels were measured by ELISA. The error bars represent the standard error ($n = 3$), p values were calculated by Dunnett's multiple comparison t-test. YVAD = Acyl-Tyr-Val-Ala-Asp-chloromethylketone.



Fig. 6. Western blot analysis of cytokine production in peritoneal macrophages following addition of bLF or bLFcin (BALB/c mice). Macrophages were incubated for 24 h in bLF (1000 μg/ml) or bLFcin (30 μg/ml). Arrows indicate increases or decreases in expression compared to the control. Data are representative of two independent experiments.

Incubation of Lewis Lung carcinoma cells in bLFcin at 100 or 300 μg/ml for 48 h significantly decreased cell number, however, bLF at 1000 μg/ml or bLFcin at 30 μg/ml had no effect on cell number (Table 1). In Western blot analysis of Lewis lung carcinoma cells treated with bLF or bLFcin for 24 h, bLF induced increased expression of IFNγ (2-fold) and IL-1β (3-fold), and bLFcin (lower doses) induced increased expression of IL-1β (4-fold) (Fig. 7).

In Western blot analysis of human cells treated with bLF or bLFcin for 24 h, both bLF and bLFcin induced expression of human lactoferrin (hLF) (2-fold) and mature IL-18 (2 ~ 4-fold) by colon cancer SW620 cells (Fig. 8A); both bLF and bLFcin induced expression of hLF (7 ~ 29-fold), IFNα (4-fold), IL-12 (2 ~ 4-fold), and mature IL-18 (2 ~ 3-fold) by mammary cancer MCF-7 cells (Fig. 8B); and both bLF and bLFcin induced expression of IFNα (4 ~ 11-fold), IL-12 (2 ~ 5-fold) and mature IL-18 (3 ~ 4-fold) by melanoma SK-MEL19 cells (Fig. 8C). SK-MEL19 cells did not express hLF. In HT29 human colon cancer cells, hLF levels were unaffected by incubation in 1000 μg/ml bLF (87% of basal line), but were significantly decreased by incubation in 30 μg/ml bLFcin (46% of basal line) (data not shown).

Table 1
Effects of lactoferrin and lactoferricin on the growth of Lewis lung carcinoma cells 5% FCS in RPMI-1640 medium, 48 h incubation

	Concentration (μg/ml)	Growth (% of Control)
bLF	1000	96.2
bLFcin	30	100.0
	100	46.5
	300	13.2



Fig. 7. Western blot analysis of cytokine production in Lewis Lung carcinoma cells following incubation with bLF or bLFcin for 24 h. Data are representative of two independent experiments.



Fig. 8. Western blot analysis of cytokine production in SW620 (A) colon cancer cells, MCF7 (B) mammary carcinoma cells, and SK-MEL19 (C) melanoma cells following incubation with bLF or bLFcin for 24 h. Data are representative of three independent experiments.

In summary, exposure of cells to bLF or bLFcin tends to cause induction of a variety of cytokines. In addition, LF may activate an autocrine loop in some cells; notice the extremely high induction of hLF in the breast cancer cell line, MCF7. The specific effects of bLF and bLFcin, however, depend on the cell type.

3.4. Anti-metastatic activity following oral administration of bLF in GKO and BALB/c mice

We have shown that bLF and bLFcin can induce mouse small intestine to increase its production of mature IL-18. An important function of IL-18 is activation of T-cells and NK cells involved in cell mediated immune responses. Through its stimulation of immune cells, IL-18 has been shown to protect experimental animals against repeated challenges with tumor cells [37,38]. Therefore, we investigated the ability of bLF to inhibit lung metastasis by Co26Lu tumor cells. In addition, we used IFNγ KO (GKO) mice to assess the importance of IFNγ on the ability of bLF to inhibit lung metastasis of Co26Lu tumor cells.

The number of lung metastatic colonies in tumor-bearing GKO mice were markedly higher than in tumor-bearing BALB/c mice (Fig. 9), indicating that IFNγ inhibits the metastatic ability of Co26Lu cells. Oral treatment with bLF significantly inhibited lung metastatic colony formation in both GKO mice and BALB/c mice (Fig. 9), indicating that bLF can inhibit the metastatic ability of Co26Lu cells in the absence of IFNγ.

3.5. Cytokine levels in the small intestines in GKO and BALB/c mice following treatment with bLF

Since IFNγ is not required for bLF-mediated inhibition of Co26Lu metastasis to the lung, we compared bLF-mediated induction of cytokines in the small intestines of GKO and BALB/c mice. IL-1β, IL-6, and TNFα levels in the mucosa of the small intestine in both GKO and BALB/c mice were not markedly changed after treatment with bLF (Fig. 10). IL-12 levels showed a tendency to decrease in BALB/c mice. IL-4 and GM-CSF showed a tendency to increase in both GKO and BALB/c mice. Mature IL-18 levels in the small intestine of GKO mice were not affected by treatment with bLF, however, bLF did cause a significant increase in mature IL-18 in BALB/c mice (Fig. 11).

Expression of IL-7, IL-15, and IL-18 mRNA was examined in freshly isolated mucosal tissues of the small intestine of GKO and BALB/c mice following treatment with bLF at 30 or 300 mg/kg per day. IL-7 mRNA levels were significantly enhanced in GKO mice by administration of bLF (1.4- and 1.5-fold increase, $p < 0.05$ and $p < 0.01$, respectively), but bLF had no effect on IL-7 mRNA levels in BALB/c mice (0.9 ~ 1.3-fold increase $p > 0.05$); bLF had no significant effect on IL-15 mRNA levels in either GKO or BALB/c mice (Fig. 12); bLF had no significant effect on IL-18 mRNA levels



Fig. 9. Effects of oral administration of bLF on the number of lung metastatic colonies in Co26Lu-bearing GKO (A) and Co26Lu-bearing BALB/c (B) female mice. The numerical values represent the median of the number of lung metastatic colonies in 15 animals. *$p < 0.05$, **$p < 0.01$ vs Control, Mann–Whitney U-test.

in GKO mice (about 1.3-fold increase, $p > 0.05$), but bLF markedly elevated IL-18 mRNA levels in BALB/c mice (1.3 and 1.7-fold increase, $p > 0.05$ and $p < 0.01$, respectively) (Fig. 12).

Thus, bLF induced expression of IL-18 mRNA and generation of mature IL-18 in BALB/c mice. Since bLF had no effect on IL-18 expression in GKO mice, bLF induction of IL-18 is IFNγ dependent. In GKO mice, bLF induced expression of IL-7.



Fig. 10. Effect of bLF on various cytokine levels in the mucosa of the small intestines of GKO and BALB/c female mice. bLF was administered orally at 30 mg/kg per day for 7 days, and 3 h after the last administration the animals were anesthetized and killed, the jejunum removed, and cytokine levels measured. Error bars represent the standard error ($n = 5$).



Fig. 11. Effect of bLF on mature IL-18 levels in the mucosa of the small intestine of GKO (A) and BALB/c (B) mice. bLF was administered orally at 30 mg/kg per day for 7 days or once at 300 mg/kg on day 7, and 3 h after last the administration the animals were anesthetized and killed, the jejunum removed, and mature IL-18 levels measured. Error bars represent the standard error ($n = 5$).



Fig. 12. Effect of bLF on the expression of IL-7, IL-15 and IL-18 mRNA in the mucosa of the small intestines of GKO (A) and BALB/c (B) female mice. bLF was administered orally at 30 mg/kg per day for 7 days or once at 300 mg/kg on day 7, and 3 h after the last administration of bLF the animals were anesthetized and killed and the jejunum removed. mRNA expression was detected by RT-PCR. Three mice were used for each condition. Expression of each transcript was normalized to β-actin and the mean expression values for each condition obtained. Numerical data represent the ratio of these values compared to the controls. Administration of bLF lead to an increase in IL-7 expression in GKO mice and to an increase in IL-18 expression in BALB/c mice. Data are representative of 2 independent experiments.

3.6. Analysis of caspase-1 expression and activity in the small intestine of GKO and BALB/c mice

Caspase-1 expression and activity in the small intestine of BALB/c mice is enhanced by treatment with bLF, and this effect is dependent on IFNγ. Therefore we investigated the role of IFNγ on bLF-mediated induction of caspase-1 expression and activity. In immunohistochemical and Western blot analysis, caspase-1 expression in epithelial cells of the small intestine was increased in both GKO and BALB/c mice after treatment with bLF (GKO: 1.6-fold; BALB/c: 1.9-fold). However, caspase-1 activity, as measured by generation of the cleaved-caspase-1 p-20 peptide, was markedly different between GKO and BALB/c mice (GKO: 0.8; BALB/c: 1.5-fold vs Control) (Fig. 13). Moreover, caspase-1 activity in the mucosa of the small intestine in GKO mice did not change following administration of bLF (120–123% of Control), but its activity in BALB/c mice was significantly enhanced (211–272% of Control, $p < 0.05$) (Table 2). Therefore, bLF induction of caspase-1 expression is not dependent on IFNγ, but generation of active caspase-1 is dependent on IFNγ.

3.7. Immunohistochemical analysis of various immune cells in the small intestine of GKO mice

bLF is thought to mediate its anti-metastasis activity by activation of immune cells in the intestine, and we have previously demonstrated that bLF increases the number of $CD4^+$ and $CD8^+$T and asialo GM_1^+ (NK) cells in BALB/c mice [9]. bLF treatment also inhibits Co26Lu metastasis to the lung in GKO mice, and this effect occurs in the absence of IFNγ, caspase-1, and IL-18. We therefore examined the effect of bLF on immune cells in the small intestine of GKO mice. $CD4^+$, IgM^+ (data not shown), and IgA^+ cells were significantly increased by treatment with bLF, but $CD8^+$ cells were not (Fig. 14).

$IL\text{-}7^+$ cells in the small intestine are mainly intraepithelial lymphocytes (IEL), fibroblasts, and vascular endothelial cells. bLF also caused a marked increase in the number of $IL\text{-}7^+$ intraepithelial lymphocytes in GKO mice (Fig. 15B). In contrast, bLF did not induce expression of IL-7 in the small intestine of BALB/c mice or an increase in $IL\text{-}7^+$ intraepithelial lymphocytes (data not shown).

$IFN\alpha^+$ cells exist in the lamina propria of the small intestine and the number of these cells was also increased by treatment with bLF in GKO mice, but not in BALB/c mice (Fig. 16). IFNα protein expression was increased (1.8-fold) as shown by Western blot analysis (data not shown).



Fig. 13. Caspase-1^{+} cells in the small intestine and Western blot analysis for procaspase-1 and active caspase-1 (caspase-1 p20). bLF was administered orally at 30 mg/kg per day for 7 days, and 3 h after the last administration of bLF the animals were anesthetized and killed, and the jejunum was removed. The results of two independent experiments are shown.

3.8. Anti-metastatic effects in tumor-bearing GKO mice by rmIL-18, rIFNαA/D, or rmIL-7 treatment

bLF inhibits Co26Lu metastasis to the lung in GKO mice in the absence of IFNγ, caspase-1, and IL-18. However, bLF induces IFNα and IL-7 in these mice. Therefore, we tested the effects of recombinant mature IL-18 (rmIL-18), recombinant IFNα (rIFNαA/D), and recombinant IL-7 (rIL-7) on Co26Lu metastasis to the lung in GKO mice. Intraperitoneal administration of IL-18 at 20 ng/mouse, IFNαA/D at 10^5 IU/mouse, or rmIL-7 at 0.1 μg/mouse caused significant retardation of tumor growth of subcutaneously implanted Co26Lu and also significant retardation of lung metastases (Table 3).

4. Discussion

LF is an important component of the innate immune system with potent antimicrobial activity and is found in a variety of exocrine secretions including gastrointestinal fluids. The small intestine has a well developed immune network that is involved in protection of the host from pathogens. For example, mucosa-associated bacteria (lactobacili and *E. coli*, etc.) in the small intestine can be potent stimulators of mononuclear cells of the intestinal lamina propria, inducing these cells to express IL-12 [39], which in turn activates intestinal immune cells and protects the small intestine against microbial infection. LF is part of the intestinal immune network [40–42]. It is an excellent marker of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease [43], and fecal LF levels are also higher in patients with colorectal tumors than in healthy individuals [44]. Because ingested LF stimulates cytokine production [8] and enhances mucosal immunity [9], NK cell activity [10,11], LAK activity [11], neutrophil activity [12,13], and macrophage cytotoxicity [14,15], it is thought that orally ingested LF is also able to interact with epithelial cells and immune cells in the mucosa of the intestine.

Table 2
Effects of bLF on caspase-1 and -3 activities in the mucosa of the small intestine in GKO and BALB/c (WT) mice

Treatment (p.o.)	Caspase-1 activity	Caspase-3 activity (absorbance at 405 nm)
GKO mice ($n = 4$)		
Control (saline)	0.035 ± 0.002	0.214 ± 0.011
bLF (30 mg/kg × 7)	0.042 ± 0.011 (1.20)	
bLF (300 mg/kg × 1)	0.043 ± 0.012 (1.23)	0.221 ± 0.024 (1.03)
BALB/c (WT) mice ($n = 5–7$)		
Control (saline)	0.018 ± 0.003*	0.168 ± 0.014
bLF (30 mg/kg × 7)	0.049 ± 0.011* (2.72)	
bLF (300 mg/kg × 1)	0.038 ± 0.005 (2.11)	0.190 ± 0.026 (1.13)

Mucosal samples of the small intestine were diluted to 200 μg protein/50 μl. () = -fold. *$p < 0.05$.

There are several reports that administration of LF inhibits tumor growth and protects against carcinogenesis [18,45,46], reviewed in refs. [26,47,48]. In several rodent cancer models, it has been shown that this protective effect is associated with enhancement of the local intestinal mucosal immune response [9,16,47,49–52].

One pathway which appears to be an effector of LF is generation of mature IL-18 and consequent activation of immune cells. Administration of bLF induces expression of IL-18 in the small intestine [9,16,46]. IL-18 stimulates both Th1 and Th2 type T helper cells, CD8^{+} effector T cells, NK cells, and LAK cells [10,11,17,53–56]; and up-regulation and/or enhanced activity of CD4^{+} and CD8^{+} effector T-lymphocytes and NK and LAK cells is also observed upon LF



Fig. 14. Effects of bLF on the number of $CD4^+$, $CD8^+$, and IgA^+ cells in the lamina propria of the small intestine of GKO mice. bLF was administered orally at 30 mg/kg per day for 7 days, and 3 h after the last administration of bLF the animals were anesthetized and killed, and the jejunum was removed and the number of $CD4^+$, $CD8^+$, and IgA^+ cells counted. Error bars represent the standard error ($n = 5$).

administration [16,19,40,50,57]. LF also stimulates the induction and/or activation of B cells, macrophages, and neutrophils [54,58,59]. Wolf et al. report that hLF resulted in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma *in vivo*, and that depletion of $CD3^+$ cells abolishes this effect [46]. Bezault et al. report that stimulation of NK cell activity is essential for LF-mediated prevention of metastasis in C57BL/6 mice: intraperitoneal administration of hLF to these mice inhibited the growth of solid tumors and prevented lung metastasis of murine melanoma cells, and this effect was lost upon deletion of NK cell function using antibody blocking experiments [18].



Fig. 15. Effects of bLF on the number of $IL\text{-}7^+$ cells in the small intestine of GKO mice. bLF was administered orally at 30 mg/kg per day for 7 days, and 3 h after the last administration of bLF the animals were anesthetized and killed, and the jejunum was removed. (A) $IL\text{-}7^+$ cells in the small intestine (arrows). (B) The number of $IL\text{-}7^+$ cells in the small intestine of GKO mice was significantly increased by treatment with bLF ($n = 5$).

In our study we confirmed the ability of bLF and digested bLF-peptides to induce expression of IL-18 and the generation of mature IL-18 in a variety of settings. Importantly, in IFNγ knockout (GKO) mice, bLF had no effect on IL-18 expression or maturation. Moreover, in settings in which bLF did induce generation of mature IL-18, maturation was abolished by caspase-1 inhibitors. Therefore, bLF-mediated induction of IL-18 expression is dependent upon IFNγ and bLF-mediated generation of mature IL-18 is dependent upon caspase-1.

Previously we showed that bLF can induce IFNγ in the intestine [50], and in this study we affirmed that bLF can induce expression of IFNγ by peritoneal macrophages and that both bLF and bLFcin can induce expression of IFNγ by Lewis Lung carcinoma cells. Moreover, bLF also induces expression



Fig. 16. Effects of bLF on the number of $IFN\alpha^+$ cells in the small intestine of GKO mice. bLF was administered orally at 30 mg/kg per day for 7 days, and 3 h after the last administration of bLF the animals were anesthetized and killed, and the jejunum was removed. (A) $IFN\alpha^+$ cells in the small intestine (arrows). (B) The number of $IFN\alpha^+$ cells in the small intestine of GKO mice was significantly increased by treatment with bLF ($n = 5$).

Table 3
Effect of IL-7, IL-18 and IFNαA/D on lung metastatic colony formation in Co26Lu-bearing GKO mice

Treatment (i.p.)	Dose (μg/mouse)	Tumor volume on day 20 (mm^3)	No. of metastatic colonies Median (range)	p-value
Control (saline)		1274 ± 254	233 (156–420)	
rmIL-7	0.1	1023 ± 68*	124 (53–165)	0.003
rmIL-7	1.0	1122 ± 172	143 (34–168)	0.007
rmIL-18	0.02	953 ± 55*	105 (51–169)	0.012
rIFNαA/D	1×10^5 IU	899 ± 59*	111 (91–168)	0.012

Cytokines were administered i.p. to Co26Lu-bearing GKO mice (5–7 mice/group) on days 10, 13, 17 and 20. *$p < 0.05$ vs Control.

of caspase-1 mRNA *in vivo*. However, while bLF administration results in generation of active caspase-1 in BALB/c mice, it has no effect on caspase-1 activity in GKO mice. Taken together, these results indicate that in BALB/c mice, bLF ingestion results in stimulation of IFNγ and caspase-1 expression; IFNγ in turn stimulates IL-18 expression and caspase-1 activity; and finally active caspase-1 cleaves pro-IL-18 to generate mature IL-18. The bLF stimulated generation of mature IL-18 subsequently acts on immune cells in the intestine which in turn effect the observed bLF anticarcinogenesis activity.

However, bLF also effects inhibition of tumor growth and metastasis in GKO mice, an animal model in which bLF administration does not result in induction of IFNγ expression or generation of caspase-1 activity or mature IL-18. This result is not inconsistent with some published reports. Kuhara et al. also report that bLF administration caused an increase in IFNγ and IL-18 and NK activity, however, bLF administration also caused increased NK activity in IL-18 KO mice [51]. In these mice, bLF induced increased expression of IFNα and IFNβ (type I IFNs) in Payer's patches and mesenteric lymph nodes, and blockade of induction of IFNα and IFNβ expression abolished bLF induction of NK activity. Using BALB/cByJ Jcl hypoglycemic mice, bLF administration does not result in elevated IFNγ or IL-18 expression [60]; however, bLF is host protective in this animal and does induce expression of IFNβ and IL-12. These cytokines are well characterized mediators of host defense against infections and cancer. bLF-mediated induction of IL-12 is also reported in other systems [61]. In the present study, we also show induction of type I IFNs and of interleukins other than IL-18 by bLF *in vitro* and in GKO mice *in vivo*. Therefore, administration of bLF can activate more than one effector pathway; which pathways are responsive to activation depend on the physiology of the gastrointestinal tract.

In the GKO mice, bLF did not induce IL-18 expression or maturation, but bLF did induce expression of IFNα and IL-7 and inhibited tumor growth and metastasis. In these mice, injection of recombinant murine IL-18 also inhibited tumor growth and metastasis. Thus, the IL-18 effector pathway is intact in GKO mice, but in the absence of IFNγ, bLF is unable to activate it. Importantly, injection of recombinant IFNαA/D or recombinant IL-7 also inhibited tumor growth and metastasis in these mice. Thus, in the absence of the IFNγ/IL-18 effector pathway, bLF is able to exert anticarcinogenesis activity by activation of a second effector pathway, an IFNα/IL-7 effector pathway.

Finally, it should be noted that bLF and bLFcin induced expression of IL-15 by peritoneal macrophages *in vitro*. That the induction of IL-15 was not observed when the entire intestinal mucosa was examined is not surprising since macrophages make up a very small proportion of this tissue. The specific role of IL-15, if any, in bLF-mediated immune modulation remains to be elucidated, however, IL-15 is a well known immune cell regulator [62–64] and could be a component of another bLF activated effector pathway.

5. Summary

Lactoferrin, originally isolated from milk, is an important component of the innate immune system. Several reports indicate that ingested lactoferrin can inhibit carcinogenesis. In this report we investigated effector pathways which link ingestion of lactoferrin to carcinogenesis. Our data support the concept that lactoferrin peptide fragments, especially lactoferricin, are able to stimulate cytokine production by cells in the mucosa of the small intestine. The subsequent activation of immune cells enhances immune surveillance, i.e., the ability of the immune system to recognize and remove malignant cells that arise during a person's lifetime, and lactoferrin's anticarcinogenesis effects are the result of this enhanced surveillance.

References

[1] R.S. Bhimani, Y. Vendrov, P. Furmanski, Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice, J. Appl. Microbiol. 86 (1999) 135–144.
[2] D. Caccavo, N.M. Pellegrino, M. Altamura, A. Rigon, L. Amati, A. Amoroso, E. Jirillo, Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application, J. Endotoxin. Res. 8 (2002) 403–417.
[3] L.A. Haversen, I. Engberg, L. Baltzer, G. Dolphin, L.A. Hanson, I. Mattsby-Baltzer, Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental *Escherichia coli* urinary tract infection in mice, Infect. Immun. 68 (2000) 5816–5823.
[4] N. Orsi, The antimicrobial activity of lactoferrin: current status and perspectives, Biometals 17 (2004) 189–196.
[5] A.C. van Hooijdonk, K.D. Kussendrager, J.M. Steijns, In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence, Br. J. Nutr. 84 (Suppl. 1) (2000) S127–S134.
[6] P.F. Levay, M. Viljoen, Lactoferrin: a general review, Haematologica 80 (1995) 252–267.
[7] M. Iigo, M. Shimamura, S. Hirano, K. Nabeshima, S. Ohkubo, Y. Tamura, H. Tsuda, Cancer prevention and anti-metastatic effect by oral administration of bovine lactoferrin, in: Tanaka T, Tsuda H (Eds.), Carcinogenesis and Modification of Carcinogenesis, Research SignPost, Kerala, India, 2005, pp. 229–242.
[8] N. Takakura, H. Wakabayashi, K. Yamauchi, M. Takase, Influences of orally administered lactoferrin on IFN-gamma and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells, Biochem. Cell Biol. 84 (2006) 363–368.
[9] W.P. Wang, M. Iigo, J. Sato, K. Sekine, I. Adachi, H. Tsuda, Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin, Jpn. J. Cancer Res. 91 (2000) 1022–1027.
[10] E. Damiens, J. Mazurier, I. el Yazidi, M. Masson, I. Duthille, G. Spik, Y. Boilly-Marer, Effects of human lactoferrin on NK cell cytotoxicity

against haematopoietic and epithelial tumour cells, Biochim. Biophys. Acta. 1402 (1998) 277–287.
[11] H. Shau, A. Kim, S.H. Golub, Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin, J. Leukoc. Biol. 51 (1992) 343–349.
[12] V. Manev, A. Maneva, L. Sirakov, Effect of lactoferrin on the phagocytic activity of polymorphonuclear leucocytes isolated from blood of patients with autoimmune diseases and *Staphylococcus aureus* allergy, Adv. Exp. Med. Biol. 443 (1998) 321–330.
[13] H. Miyauchi, S. Hashimoto, M. Nakajima, I. Shinoda, Y. Fukuwatari, H. Hayasawa, Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain, Cell. Immunol. 187 (1998) 34–37.
[14] L. Edde, R.B. Hipolito, F.F. Hwang, D.R. Headon, R.A. Shalwitz, M.P. Sherman, Lactoferrin protects neonatal rats from gut-related systemic infection, Am. J. Physiol. Gastrointest. Liver Physiol 281 (2001) G1140–G1150.
[15] P. Puddu, M.G. Carollo, F. Belardelli, P. Valenti, S. Gessani, Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages, J. Leukoc. Biol. 82 (2007) 347–353.
[16] T. Kuhara, M. Iigo, T. Itoh, Y. Ushida, K. Sekine, N. Terada, H. Okamura, H. Tsuda, Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium, Nutr. Cancer 38 (2000) 192–199.
[17] I. Okamoto, K. Kohno, T. Tanimoto, H. Ikegami, M. Kurimoto, Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12, J. Immunol 162 (1999) 3202–3211.
[18] J. Bezault, R. Bhimani, J. Wiprovnick, P. Furmanski, Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice, Cancer Res. 54 (1994) 2310–2312.
[19] M. Iigo, T. Kuhara, Y. Ushida, K. Sekine, M.A. Moore, H. Tsuda, Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice, Clin. Exp. Metastasis 17 (1999) 35–40.
[20] Y.C. Yoo, S. Watanabe, R. Watanabe, K. Hata, K. Shimazaki, I. Azuma, Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice, Jpn. J. Cancer Res. 88 (1997) 184–190.
[21] C. Masuda, H. Wanibuchi, K. Sekine, Y. Yano, S. Otani, T. Kishimoto, H. Tsuda, S. Fukushima, Chemopreventive effects of bovine lactoferrin on *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis, Jpn. J. Cancer Res. 91 (2000) 582–588.
[22] T. Tanaka, K. Kawabata, H. Kohno, S. Honjo, M. Murakami, T. Ota, H. Tsuda, Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats, Jpn. J. Cancer Res. 91 (2000) 25–33.
[23] Y. Ushida, K. Sekine, T. Kuhara, N. Takasuka, M. Iigo, H. Tsuda, Inhibitory effects of bovine lactoferrin on intestinal polyposis in the Apc(Min) mouse, Cancer Lett. 134 (1998) 141–145.
[24] Y. Ushida, K. Sekine, T. Kuhara, N. Takasuka, M. Iigo, M. Maeda, H. Tsuda, Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat, Jpn. J. Cancer Res. 90 (1999) 262–267.
[25] K. Sekine, Y. Ushida, T. Kuhara, M. Iigo, H. Baba-Toriyama, M.A. Moore, M. Murakoshi, Y. Satomi, H. Nishino, T. Kakizoe, H. Tsuda, Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane, Cancer Lett. 121 (1997) 211–216.
[26] H. Tsuda, K. Sekine, Y. Ushida, T. Kuhara, N. Takasuka, M. Iigo, B.S. Han, M.A. Moore, Milk and dairy products in cancer prevention: focus on bovine lactoferrin, Mutat. Res. 462 (2000) 227–233.
[27] D.K. Dalton, S. Pitts-Meek, S. Keshav, I.S. Figari, A. Bradley, T.A. Stewart, Multiple defects of immune cell function in mice with disrupted interferon-gamma genes, Science 259 (1993) 1739–1742.
[28] T.E. Carey, T. Takahashi, L.A. Resnick, H.F. Oettgen, L.J. Old, Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells, Proc. Natl. Acad. Sci. USA 73 (1976) 3278–3282.
[29] D.M. Anderson, L. Johnson, M.B. Glaccum, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, V. Valentine, M.N. Kirstein, D.N. Shapiro, S.W. Morris, et al., Chromosomal assignment and genomic structure of Il15, Genomics 25 (1995) 701–706.
[30] A.E. Namen, S. Lupton, K. Hjerrild, J. Wignall, D.Y. Mochizuki, A. Schmierer, B. Mosley, C.J. March, D. Urdal, S. Gillis, Stimulation of B-cell progenitors by cloned murine interleukin-7, Nature 333 (1988) 571–573.
[31] M.A. Nett, D.P. Cerretti, D.R. Berson, J. Seavitt, D.J. Gilbert, N.A. Jenkins, N.G. Copeland, R.A. Black, D.D. Chaplin, Molecular cloning of the murine IL-1 beta converting enzyme cDNA, J. Immunol 149 (1992) 3254–3259.
[32] H. Okamura, H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al., Cloning of a new cytokine that induces IFN-gamma production by T cells, Nature 378 (1995) 88–91.
[33] H. Kuwata, K. Yamauchi, S. Teraguchi, Y. Ushida, Y. Shimokawa, T. Toida, H. Hayasawa, Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats, J. Nutr 131 (2001) 2121–2127.
[34] T. Ghayur, S. Banerjee, M. Hugunin, D. Butler, L. Herzog, A. Carter, L. Quintal, L. Sekut, R. Talanian, M. Paskind, W. Wong, R. Kamen, D. Tracey, H. Allen, Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production, Nature 386 (1997) 619–623.
[35] Y. Gu, K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M.A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakanishi, M. Kurimoto, T. Tanimoto, R.A. Flavell, V. Sato, M.W. Harding, D.J. Livingston, M.S. Su, Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme, Science 275 (1997) 206–209.
[36] N. Saha, F. Moldovan, G. Tardif, J.P. Pelletier, J.M. Cloutier, J. Martel-Pelletier, Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18, Arthritis Rheum 42 (1999) 1577–1587.
[37] M.J. Micallef, T. Tanimoto, K. Kohno, M. Ikeda, M. Kurimoto, Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma, Cancer Res. 57 (1997) 4557–4563.
[38] M.J. Micallef, K. Yoshida, S. Kawai, T. Hanaya, K. Kohno, S. Arai, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, M. Kurimoto, In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites, Cancer Immunol, Immunother 43 (1997) 361–367.
[39] C. Hessle, L.A. Hanson, A.E. Wold, Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production, Clin. Exp. Immunol 116 (1999) 276–282.
[40] D. Legrand, E. Elass, A. Pierce, J. Mazurier, Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties, Biometals 17 (2004) 225–229.
[41] D. Legrand, E. Elass, M. Carpentier, J. Mazurier, Lactoferrin: a modulator of immune and inflammatory responses, Cell. Mol. Life Sci. 62 (2005) 2549–2559.
[42] P.P. Ward, S. Uribe-Luna, O.M. Conneely, Lactoferrin and host defense, Biochem. Cell Biol. 80 (2002) 95–102.
[43] K. Uchida, R. Matsuse, S. Tomita, K. Sugi, O. Saitoh, S. Ohshiba, Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer, Clin. Biochem. 27 (1994) 259–264.
[44] I. Hirata, M. Hoshimoto, O. Saito, M. Kayazawa, T. Nishikawa, M. Murano, K. Toshina, F.Y. Wang, R. Matsuse, Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases, World J. Gastroenterol 13 (2007) 1569–1574.
[45] J.S. Wolf, D. Li, R.J. Taylor, B.W. O'Malley Jr., Lactoferrin inhibits growth of malignant tumors of the head and neck, ORL J, Otorhinolaryngol. Relat. Spec. 65 (2003) 245–249.
[46] J.S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X. Zhang, R.J. Taylor, S.E. Strome, B.W. O'Malley Jr., Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo, Clin. Cancer Res. 13 (2007) 1601–1610.

[47] H. Tsuda, K. Sekine, K. Fujita, M. Iigo, Cancer prevention by bovine lactoferrin and underlying mechanisms—a review of experimental and clinical studies, Biochem. Cell Biol. 80 (2002) 131–136.
[48] H. Tsuda, K. Fukamachi, J. Xu, K. Sekine, S. Ohkubo, N. Takasuka, M. Iigo, Prevention of carcinogenesis and cancer metastasis by bovine lactoferrin, Prod. Jpn. Acad. 82 (2006) 208–215.
[49] K. Fujita, E. Matsuda, K. Sekine, M. Iigo, H. Tsuda, Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats, Carcinogenesis 25 (2004) 1961–1966.
[50] M. Iigo, M. Shimamura, E. Matsuda, K. Fujita, H. Nomoto, J. Satoh, S. Kojima, D.B. Alexander, M.A. Moore, H. Tsuda, Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis, Cytokine 25 (2004) 36–44.
[51] T. Kuhara, K. Yamauchi, Y. Tamura, H. Okamura, Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine, J. Interferon Cytokine Res. 26 (2006) 489–499.
[52] M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, G. Forni, Requirement for IFN-gamma, CD8+T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors, Cancer Res. 67 (2007) 6425–6432.
[53] C.A. Dinarello, Interleukin-18, Methods 19 (1999) 121–132.
[54] D.A. Horwitz, A.C. Bakke, W. Abo, K. Nishiya, Monocyte and NK cell cytotoxic activity in human adherent cell preparations: discriminating effects of interferon and lactoferrin, J. Immunol 132 (1984) 2370–2374.
[55] K. Nakanishi, T. Yoshimoto, H. Tsutsui, H. Okamura, Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu, Cytokine Growth Factor Rev. 12 (2001) 53–72.
[56] K. Nakanishi, T. Yoshimoto, H. Tsutsui, H. Okamura, Interleukin-18 regulates both Th1 and Th2 responses, Annu. Rev. Immunol 19 (2001) 423–474.
[57] A. Varadhachary, J.S. Wolf, K. Petrak, B.W. O'Malley Jr., M. Spadaro, C. Curcio, G. Forni, F. Pericle, Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy, Int. J. Cancer 111 (2004) 398–403.
[58] M. Gahr, C.P. Speer, B. Damerau, G. Sawatzki, Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes, J. Leukoc. Biol. 49 (1991) 427–433.
[59] T. Yoshimoto, H. Okamura, Y.I. Tagawa, Y. Iwakura, K. Nakanishi, Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells, Proc. Natl. Acad. Sci. USA 94 (1997) 3948–3953.
[60] H. Wakabayashi, N. Takakura, K. Yamauchi, Y. Tamura, Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin, Clin. Vaccine Immunol 13 (2006) 239–245.
[61] S.A. Hwang, K.M. Wilk, Y.A. Bangale, M.L. Kruzel, J.K. Actor, Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes, Med. Microbiol. Immunol 196 (2007) 171–180.
[62] K. Inagaki-Ohara, H. Nishimura, A. Mitani, Y. Yoshikai, Interleukin-15 preferentially promotes the growth of intestinal intraepithelial lymphocytes bearing gamma delta T cell receptor in mice, Eur. J. Immunol 27 (1997) 2885–2891.
[63] T. Ohteki, S. Ho, H. Suzuki, T.W. Mak, P.S. Ohashi, Role for IL-15/IL-15 receptor beta-chain in natural killer 1.1+T cell receptor-alpha beta+ cell development, J. Immunol 159 (1997) 5931–5935.
[64] A. Okazawa, T. Kanai, K. Nakamaru, T. Sato, N. Inoue, H. Ogata, Y. Iwao, M. Ikeda, T. Kawamura, S. Makita, K. Uraushihara, R. Okamoto, M. Yamazaki, M. Kurimoto, H. Ishii, M. Watanabe, T. Hibi, Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes, Clin. Exp. Immunol 136 (2004) 269–276.

Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma

Kazu Shiomi,[1] Yoshiaki Hagiwara,[6] Kouji Sonoue,[1] Tatsuya Segawa,[6] Kazuya Miyashita,[6] Masahiro Maeda,[6] Hiroshi Izumi,[1] Kimihiko Masuda,[3] Masataka Hirabayashi,[7] Takao Moroboshi,[8] Takashi Yoshiyama,[4] Atsuko Ishida,[9] Yuji Natori,[5] Akira Inoue,[10] Masashi Kobayashi,[7] Yukinori Sakao,[1] Hideaki Miyamoto,[1] Kazuhisa Takahashi,[1] and Okio Hino[2]

Abstract **Background:** Because mesothelioma initially progresses on the surface of the pleura and peritoneum without forming masses, it has been difficult to diagnose at an early stage. It would be very useful to identify a tumor marker that could be used for screening to enable more diagnoses to be made at an early, treatable stage.

Materials and Methods: We had previously identified N-ERC/mesothelin as a potential biomarker for mesothelioma. In the current work, we used a newly developed ELISA system to gain data on N-ERC/mesothelin levels in various clinical settings. A total of 102 healthy volunteers were recruited. In addition, 39 patients were diagnosed with mesothelioma, 53 patients were diagnosed with diseases that should be distinguished from mesothelioma, and 201 subjects were diagnosed with asbestos-related nonmalignant diseases (including simple exposure to asbestosis) who were treated at any of the cooperating hospitals were enrolled.

Results: Serum N-ERC/mesothelin levels measured by a new ELISA system showed that the median values from patients with mesothelioma were extremely high compared with levels obtained from other patients. Analysis in terms of histologic type showed that serum levels of N-ERC/mesothelin were elevated in epithelioid type mesothelioma, especially. In four important models of clinical settings, the sensitivity and specificity of N-ERC/mesothelin were about 71% to 90% and 88% to 93%, respectively.

Conclusion: N-ERC/mesothelin is a very promising tumor marker for mesothelioma, especially epithelioid mesothelioma.

Mesothelioma initially progresses along the surfaces of the pleura and peritoneum without forming masses; it is anatomically difficult to diagnose at an early stage and to completely remove with surgery. Moreover, mesothelioma typically has a long incubation period before it becomes clinically evident among high-risk individuals with severe exposure to asbestos. Sugarbaker et al. (1) has reported a groundbreaking result: for patients with early stage disease, 5-year survival after trimodality therapy exceeded 40%. This finding that early disease may be effectively treated emphasizes the importance of identifying a tumor marker that is practical for screening and can allow physicians to make an early diagnosis.

Recently, osteopontin, soluble mesothelin-related protein, and serum mesothelin have been reported as candidates for a mesothelioma tumor marker (2–7). We have postulated (8) that another product may be useful as a tumor marker: N-ERC/mesothelin, a NH_2 terminal 31-kDa fragment of mesothelin gene products that was first cloned as a megakaryocyte-potentiating factor in humans and that is physiologically secreted into blood. Since the time of that report, we have established a new ELISA system that detects the NH_2 terminal fragments of ERC/mesothelin products at a higher sensitivity and specificity. The current work was done to obtain data for

Authors' Affiliations: [1]Department of General Thoracic Surgery, Respiratory Medicine, Human Pathology and [2]Department of Pathology and Oncology, Juntendo University, School of Medicine; [3]Department of Respiratory Diseases, National Organization Tokyo Hospital; [4]Department of Respiratory Medicine, Fukujuji Hospital, Japan Antituberculosis Association; [5]Hirano Kameido Himawari Clinic, Tokyo, Japan; [6]Immuno-Biological Laboratories Co., Ltd., Gunma, Japan; [7]Department of Respiratory Medicine, Hyogo Prefectural Tsukaguchi Hospital, Hyogo, Japan; [8]Division of General Thoracic Surgery, Yokosuka Kyosai Hospital; [9]Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan; and [10]Respiratory Medicine and Translational Research Clinic, Tohoku University Hospital, Miyagi, Japan

Received 6/30/07; revised 11/14/07; accepted 11/20/07.

Grant support: Grant-in-aid for Cancer Research and grants-in-aid for Scientific Research from Ministry of Education, Culture, Sports, and Science and Technology of Japan and Ministry of Health, Labor, and Welfare of Japan. This study was partially supported by a consignment expense for Molecular Imaging Program on "Research Base for PET Diagnosis" from Ministry of Education, Culture, Sports, and Science and Technology, Government of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Okio Hino, Department of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. E-mail: ohino@med.juntendo.ac.jp.

©2008 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-1613

N-ERC/mesothelin with use of the new ELISA system in various clinical settings and to compare its data with that of the previous ELISA system.

Materials and Methods

Preparation of novel anti-ERC/mesothelin antibodies. The anti-N-ERC/mesothelin monoclonal antibody (MoAb) clone 7E7 has been previously reported (8). We established a novel MoAb clone in the same way. Briefly, N-ERC/mesothelin, expressed in *Escherichia coli* as glutathione *S*-transferase–tagged and histidine-tagged fusion proteins, was purified and used as an immunogen. Splenocytes from immunized mice were fused with myeloma cell line X63-Ag8.653. Supernatants of the hybridoma cells were screened for reactivity to immunogen using ELISA, and several positive clones were selected by limiting dilution method. One novel clone, 16K16, was chosen for use with the new ELISA system in this study.

Cell culture, protein expression, and Western blot analysis. CHO-K1 cells were cultured in DMEM supplemented with 10% FCS. Full-length cDNA of the ERC/mesothelin coding region was inserted into the pcDNA3.1(+) vector (Invitrogen) to enable expression in CHO-K1 cells. Transfection was done using FuGENE6 transfection reagent (Roche-Diagnostics). A stable transfectant of CHO-K1 cells that expressed ERC/mesothelin protein was screened by G418 resistance and established as the cell line for further study.

Culture supernatants and ERC/mesothelin/CHO-K1 transfectant cells were harvested. CHO-K1 cells containing expressed ERC/mesothelin protein were lysed in a solution containing 2% SDS, 10% glycerol, 50 mmol/L Tris-HCl (pH 6.8), and 100 mmol/L DTT, and then boiled. The crude lysates and culture supernatants were electrophoresed on 12.5% Laemmli gels and transferred to polyvinylidene fluoride membranes. Two identical membranes were blocked in 1% skim milk in PBS with 0.1% Tween 20 (PBS-T) for 1 h at room temperature. Next, one of the two membranes was incubated with 1 μg/mL 7E7 MoAb; the other was incubated with 16K16 MoAb in 1% skim milk with PBS-T for an additional 1 h at room temperature. Secondary antibodies in the form of rabbit anti-mouse immunoglobulin conjugated to peroxidase (IBL) were then added and allowed to react with the membranes for 1 h longer at room temperature. ERC/mesothelin on the membranes was visualized by the enhanced chemiluminescence detection system (Amersham Biosciences).

Epitope mapping of MoAbs against N-ERC/mesothelin. The epitopes of MoAb-7E7 and MoAb-16K16 were searched against a series of deletion mutants of recombinant N-ERC/mesothelin protein expressed in an *in vitro* translation system using wheat germ extract. The cDNA of N-ERC/mesothelin was inserted into pEU vector (CellFree Sciences) as a glutathione *S*-transferase–tagged protein. A series of cDNA coding deletion mutants of recombinant N-ERC/mesothelin protein was amplified by PCR reactions with a series of antisense primers, each of which was displaced by 18 nucleotides from the COOH terminal region of N-ERC/mesothelin, then transcribed and translated in an *in vitro* protein expression system (ENDEXT Wheat Germ Expression Premium Kit, CellFree Sciences), according to the manufacturer's protocol. A series of recombinant proteins of deletion mutant N-ERC/mesothelin was applied to Dot blotting analysis with MoAb-7E7 and MoAb-16K16 to determine epitopes of each MoAb, as described in the paragraph of Western blotting.

Novel sandwich ELISA using MoAb-16K16. A novel sandwich ELISA system using clone 16K16 was established in the same manner as described previously (8). Microtiter plates (96 wells) were coated with 100 μL/well 100 mmol/L carbonate buffer (pH 9.5) containing purified 7E7 MoAb and allowed to adhere overnight at 4°C. Plates were washed with PBS-T and blocked for 1 h at room temperature with 200 μL/well 1% (w/v) bovine serum albumin in PBS containing 0.05% NaN_3. After three washes with PBS-T, 100-μL aliquots of test samples or recombinant N-ERC/mesothelin as a standard, serially diluted in 1% bovine serum albumin in PBS-T, were added in duplicate to wells and incubated at 37°C for 1 h. After seven washes with PBS-T, 100 μL horseradish peroxidase–conjugated MoAb-16K16 mouse IgG was added to each well and incubated for 30 min at 4°C. Wells were washed nine times with PBS-T, then 100 μL freshly prepared tetramethyl benzidine solution was added to each well as a substrate and incubated in the dark for 30 min at room temperature. The reaction was terminated by addition of 100 μL of 1 N H_2SO_4. Absorbance of the solution at 450 nm was measured in an ELISA reader (E-Max, Molecular Devices Co.). Recombinant N-ERC/mesothelin used as the standard protein in the ELISA system was purified from culture supernatants of



Fig. 1. *A*, characterization of anti–N-ERC/mesothelin antibodies by Western blot analysis. Lanes 2 and 4, culture supernatant and lysate of CHO-K1 cells transfected with ERC/mesothelin cDNA, respectively; lanes 1 and 3, culture supernatant and lysate of mock/CHO cells, respectively. *B*, epitopes of antibodies in N-ERC/mesothelin ELISA system. Epitope mapping for MoAbs revealed that the epitope of MoAb-7E7 was in amino acids 134 to 139 of N-ERC/mesothelin. Similarly, MoAb-16K16 recognized amino acids 68 to 73 of the N-ERC/mesothelin protein. The new ELISA system uses MoAb-7E7 and MoAb-16K16. The previous ELISA system used MoAb-7E7 and polyclonal antibody 282. *C*, standard dose-response curves for new ELISA system (7-16) for N-ERC/mesothelin.